Lipid disorders involving derangements in serum cholesterol, triglycerides, or both are
commonly encountered in clinical practice and often have implications for cardiovascular …

Elevations in plasma triglyceride are the result of overproduction and impaired clearance of
triglyceride-rich lipoproteins—very low-density lipoproteins (VLDL) and chylomicrons …

Background High triglyceride levels are associated with increased cardiovascular risk, but
whether reductions in these levels would lower the incidence of cardiovascular events is …

Peroxisome proliferator–activated receptors (PPARs) regulate energy metabolism and
hence are therapeutic targets in metabolic diseases such as type 2 diabetes and non …

Cardiovascular disease (CVD) remains the leading cause of morbidity and mortality for
patients with type 2 diabetes, despite recent significant advances in management strategies …

Even at low-density lipoprotein cholesterol (LDL-C) goal, patients with cardiometabolic
abnormalities remain at high risk of cardiovascular events. This paper aims (i) to critically …

Insulin resistance is a key feature of the metabolic syndrome and often progresses to type 2
diabetes. Both insulin resistance and type 2 diabetes are characterized by dyslipidemia …

PPARα is a nuclear receptor that regulates liver and skeletal muscle lipid metabolism as
well as glucose homeostasis. Acting as a molecular sensor of endogenous fatty acids (FAs) …

Aims To update the evidence about the diabetogenic effect of statins. Methods We searched
for randomized-controlled trials reporting the effects of statin therapy on glycosylated …

Subnormal plasma levels of high-density lipoprotein cholesterol (HDL-C) constitute a major
cardiovascular risk factor; raising low HDL-C levels may therefore reduce the residual …